Yahoo
KSE - Delayed Quote KRW

Samsung Biologics Co.,Ltd. (207940.KS)

1,516,000.00 -4,000.00 (-0.26%)
At close: 3:30:27 PM GMT+9
Chart Range Bar
Loading chart for 207940.KS
  • Previous Close 1,520,000.00
  • Open 1,505,000.00
  • Bid 1,515,000.00 x --
  • Ask 1,516,000.00 x --
  • Day's Range 1,480,000.00 - 1,578,000.00
  • 52 Week Range 1,150,000.00 - 1,987,000.00
  • Volume 102,765
  • Avg. Volume 57,966
  • Market Cap (intraday) 70.575T
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date (est.) Jan 20, 2027
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 1,879,148.12

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.

samsungbiologics.com

5,326

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

207940.KS
10.56%
KOSPI Composite Index (^KS11)
20.06%

1-Year Return

207940.KS
19.25%
KOSPI Composite Index (^KS11)
25.66%

3-Year Return

207940.KS
34.70%
KOSPI Composite Index (^KS11)
102.20%

5-Year Return

207940.KS
15.33%
KOSPI Composite Index (^KS11)
70.40%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 1.49T
Earnings 391.1B
Profit Margin 26.24%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
500B
1T
28.0%
30.0%
32.0%
34.0%
36.0%

Analyst Insights

View More

Analyst Price Targets

1,350,000.00 Low
1,879,148.12 Average
1,516,000.00 Current
2,200,000.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    38.75%

  • Return on Assets (ttm)

    9.57%

  • Return on Equity (ttm)

    18.53%

  • Revenue (ttm)

    5.12T

  • Net Income Avi to Common (ttm)

    1.85T

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.21T

  • Total Debt/Equity (mrq)

    14.84%

  • Levered Free Cash Flow (ttm)

    1.3T

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: